Xando Díaz-Villamarín
Xando Díaz-Villamarín
H.U. San Cecilio - Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e
Verified email at juntadeandalucia.es
TitleCited byYear
Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent
J Sánchez-Ramos, CL Dávila-Fajardo, PT Frías, XD Villamarín, ...
International journal of cardiology 225, 289-295, 2016
A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed Spanish population
HY Tong, CL Dávila-Fajardo, AM Borobia, LJ Martínez-González, ...
PloS one 11 (3), e0150456, 2016
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty
X Díaz-Villamarín, CL Dávila-Fajardo, LJ Martínez-González, ...
Pharmacogenomics 17 (12), 1327-1338, 2016
Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine
CL Dávila-Fajardo, X Díaz-Villamarín, A Antúnez-Rodríguez, ...
Genes 10 (4), 261, 2019
Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention
V Fragoulakis, M Bartsakoulia, X Díaz-Villamarín, K Chalikiopoulou, ...
The Pharmacogenomics Journal, 1, 2019
The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention …
CL Dávila-Fajardo, J Sánchez-Ramos, X Diaz-Villamarín, ...
Data in brief 10, 518-524, 2017
The system can't perform the operation now. Try again later.
Articles 1–6